SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ____________________  FORM
10-Q ____________________  [X] QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934  For the quarterly period ended March 31,
2009  [  ] TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15 ( d ) OF THE EXCHANGE ACT  For the transition period from
____________ to____________  Commission File No. 000-49655  LIPIDVIRO TECH, INC. (Exact name of registrant as specified in
its charter)  Nevada
87-0678927(State or Other Jurisdiction of
(I.R.S. Employer Identification No.)incorporation or organization)  4685 S. Highland Drive, Suite #202 Salt Lake City, Utah  84117 (Address of Principal Executive Offices)  (801) 278-9424 (Registrants telephone number, including
area code)  1338 S. Foothill Drive, #126 Salt Lake City, Utah  84108 (Former name, former address and former
fiscal year, if changed since last report)  Indicate by check mark whether the
Registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days. Yes [X]
No [  ]  Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company.  See definition of large
accelerated filer, accelerated filer and smaller reporting company in Rule
12b-2 of the Exchange Act.  (Check one):  Large accelerated filer   [  ]
                                                                     Accelerated
filer [  ]  Non-accelerated filer     [  ]
                                                                     Smaller
reporting company  [X] (Do not check if a smaller reporting company)  Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes [ X ] No [  ]  1     APPLICABLE ONLY TO ISSUERS INVOLVED IN
BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE
YEARS  Indicate by check mark whether the
registrant has filed all documents and reports required to be filed by Sections
12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the
distribution of securities under a plan confirmed by a court.  Not applicable.  APPLICABLE ONLY TO CORPORATE ISSUERS  Indicate the number of shares outstanding of each of the
issuers classes of common stock, as of the latest practicable date:  May
8, 2009 - 1,305,344 shares of common stock.  PART I   Item 1.  Financial Statements  The financial statements of LipidViro Tech,
Inc., a Nevada corporation (the Company, we, our or us), required to be
filed with this 10-Q Quarterly Report were prepared by management and commence
below, together with related notes. In the opinion of management, the financial
statements fairly present the financial condition of the Company.      2           LIPIDVIRO TECH, INC. (A Development Stage Company) MARCH 31, 2009 UNAUDITED CONDENSED FINANCIAL
STATEMENTS  3       TABLE OF CONTENTS  PAGE   Unaudited Condensed Balance Sheets, March
31, 2009 and December 31, 2008 5   Unaudited Condensed Statements of
Operations, for the three
months ended March 31, 2009 and 2008 and for the period from
inception on May 6, 2003
through March 31, 2009 6   Unaudited Condensed Statements of
Cash Flows, for the three
months ended March 31, 2009 and 2008 and for the period from
inception on May 6, 2003
through March 31, 2009 7    Notes
to Unaudited Condensed Financial Statements 9 - 12  4


LIPIDVIRO TECH,
INC. (A Development Stage Company) UNAUDITED CONDENSED BALANCE SHEETS  ASSETS March 31,
2009

December 31, 2008CURRENT ASSETS:TOTAL
ASSETS
$
-

$
-LIABILITIES AND STOCKHOLDERS EQUITY
(DEFICIT)CURRENT LIABILITIES:Accounts
payable
$
52,023

$
41,540Accounts payable
subject to indemnification

178,112


178,112Related party
loans

55,024


49,513Total
Current Liabilities

285,159


269,165STOCKHOLDERS EQUITY (DEFICIT):Common Stock, $.001 par value,
150,000,000 shares authorized,
1,305,344 and
1,305,334 shares issued and outstanding, respectively

1,305


1,305Capital in excess of par value

4,852,612


4,852,612Deficit accumulated during the
development stage

(5,139,076)


(5,123,082)Total
Stockholders Equity (Deficit)

(285,159)


(269,165)TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
$
-

$
-     The accompanying notes are an integral part
of these financial statements.


5


LIPIDVIRO TECH,
INC. (A Development Stage Company) UNAUDITED CONDENSED STATEMENTS OF
OPERATIONS   For the Three Months Ended
March 31,

For the Period From Inception On May
6, 2003 through
March 31,2009

2008

2009REVENUE
$
-
$
-
$
-OPERATING EXPENSES:Consulting

-

-

564,269Employee compensation

-

13,437

322,598Professional fees

14,938

27,948

376,280Other general and administrative

-

2

101,282Total Operating
Expenses

14,938

41,387

1,364,429OPERATING LOSS

(14,938)

(41,387)

(1,364,429)OTHER EXPENSE:Related party interest expense

(1,056)

(14,940)

(1,567,068)LOSS FROM CONTINUING OPERATIONS BEFORE INCOME
TAXES

(15,994)

(56,327)

(2,931,497)PROVISION FOR INCOME TAXES

-

-

-LOSS FROM CONTINUING OPERATIONS

(15,994)

(56,327)

(2,931,497)DISCONTINUED OPERATIONS:Income (loss) from operations of
discontinued
research
business

-

(54,259)

(2,207,579)Income tax expense

-

-

-INCOME (LOSS) FROM DISCONTINUED OPERATIONS

-

(54,259)

(2,207,579)NET INCOME (LOSS)
$
(15,994)
$
(110,586)
$
(5,139,076)BASIC AND DILUTED INCOME (LOSS) PER SHAREContinuing operations
$
(0.01)
$
(0.04)Discontinued Operations

-

(0.04)Net income (loss)
$
(0.01)
$
(0.08)WEIGHTED AVERAGE SHARES OUTSTANDING

1,305,344

1,302,645   The accompanying notes are an integral part
of these financial statements.


6


LIPIDVIRO TECH,
INC. (A Development Stage Company) UNAUDITED CONDENSED STATEMENTS OF CASH
FLOWS   For the Three Months Ended
March 31,

For the Period From Inception On May
6, 2003 through
March 31,2009

2008

2009CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)
$
(15,994)
$
(110,586)
$
(5,139,076)Adjustments to reconcile net income
(loss) to net cash
used by operating
activities:Depreciation

-

187

3,393Expense costs related to
unsuccessful financing
Transaction

-

-

31,900Gain on settlement of
debt

-

-

(250,082)Imputed interest
expense

-

-

42,377Noncash expenses paid by a
shareholder

-

-

6,900Noncash expenses paid by
issuance of common stock

-

-

1,346,919Noncash services paid by
issuance of common stock

-

41,813

1,239,726Noncash services paid by
grant of warrants

-

24,340

1,460,695Net increase (decrease) in
operating liabilities:Accounts payable

10,483

22,788

343,208Related party loans -
interest

1,056

7,481

88,501Related party accrued
interest

-

7,459

90,020Net Cash
Used by Operating Activities

(4,455)

(6,518)

(735,519)CASH FLOWS FROM INVESTING ACTIVITIES:
Cash of LTU

-

-

(25)Payments for property and
equipment

-

-

(3,675)Payments for definite-life
intangible assets

-

-

(33,632)Payments for goodwill

-

-

(269,006)Net Cash
Used by Investing Activities

-

-

(306,338)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from related party
loans

4,455

5,463

684,214Payments on related party
loans

-

-

(8,700)Proceeds from capital
contributions

-

1,072

34,133Proceeds from common stock
issuances

-

-

293,700Proceeds from sale of
warrants

-

-

38,510Net Cash
Provided by Financing Activities

4,455

6,535

1,041,857  (Continued)


7


LIPIDVIRO TECH,
INC. (A Development Stage Company) UNAUDITED CONDENSED STATEMENTS OF CASH
FLOWS (Continued) For the Three Months Ended
March 31,

For the Period From Inception On May
6, 2003 through
March 31,2009

2008

2009NET INCREASE (DECREASE) IN CASH

-

17

-CASH AT BEGINNING OF PERIOD

-

46

-CASH AT END OF PERIOD
$
-
$
63
$
-SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:
Cash paid during the period for:Interest
$
-
$
-
$
-Income Taxes
$
-
$
-
$
-SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND
FINANCING ACTIVITIES:Liabilities settled by disposition of
LTU with $25
in cash, $282 in net
property and equipment, $290,317
in goodwill, and $19,074 in
accounts payable at the
time of disposition
$
-
$
-
$
1,209,297Liabilities settled by transferring
patents of 34,637
$
-
$
-
$
284,719Definite-life intangible asset fees
accrued in accounts
Payable
$
-
$
-
$
1,005Deferred financing costs paid
 through issuance of
common stock
$
-
$
-
$
31,900Common stock repurchased through
issuance of
$600,000 note payable and
$1 paid by a shareholder
$
-
$
-
$
600,001Common stock issued to purchase
minority interest
$
-
$
-
$
21,311   The accompanying notes are an integral part
of these financial statements.


8


LIPIDVIRO TECH,
INC. (A Development Stage Company) NOTES TO THE UNAUDITED CONDENSED FINANCIAL
STATEMENTS  NOTE 1  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  The accompanying financial statements have been prepared
by the Company in accordance with Article 8 of U.S. Securities and Exchange
Commission Regulation S-X.  In the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to present fairly
the financial position, results of operations and cash flows at March 31, 2009
and 2008 and for the periods then ended have been made. Certain information and
footnote disclosures normally included in financial statements prepared in
accordance with U.S. generally accepted accounting principles have been
condensed or omitted.  It is suggested that these condensed financial
statements be read in conjunction with the financial statements and notes
thereto included in the Company's December 31, 2008 audited financial
statements.  The results of operations for the periods ended March 31, 2009
and 2008 are not necessarily indicative of the operating results for the full
year.  NOTE 2  GOING CONCERN  The Companys financial statements have been presented on
the basis that it is a going concern, which contemplates the realization of
assets and the satisfaction of liabilities in the normal course of business.
 At March 31, 2009, the Company had incurred losses since inception, had no
revenue-generating activities, had negative cash flows from operating
activities, and had current liabilities in excess of current assets.  These
factors create an uncertainty about the Companys ability to continue as a going
concern.  In this regard, management is proposing to raise any necessary
additional funds not provided by operations through loans or through additional
sales of common stock.  There is no assurance that the Company will be
successful in raising this additional capital or in achieving profitable
operations.  The financial statements do not include any adjustments that
might be necessary if the Company is unable to continue as a going concern.  NOTE 3  DISCONTINUED OPERATIONS  Operations of the research business have been
reclassified in the statements of operations for all periods presented.
 The following is a summary of the results of operations of the
discontinued research business.


|                                         |                                      |   |                                                                     |   |          |  |   |            
|---------------------------------------- | ------------------------------------ | - | ------------------------------------------------------------------- | - | -------- |  | - | -----------
|                                         | For the Three Months Ended
March 31, |   | For the Period From Inception on May
6, 2003 Through March 31, 2009
|                                         | 2009                                 |   | 2008                                                                |  
|Revenue                                  | $                                    | - |                                                                     | $ | -        |  | $ | -          
|General and administrative               |                                      | - |                                                                     |   | (1,181)  |  |   | (47,246)   
|Research and development                 |                                      | - |                                                                     |   | (52,972) |  |   | (2,410,307)
|Gain on settlement of debt               |                                      | - |                                                                     |   | -        |  |   | 250,082    
|Interest income                          |                                      | - |                                                                     |   | -        |  |   | 23         
|Foreign currency transaction gain (loss) |                                      | - |                                                                     |   | (106)    |  |   | (131)      
|Income taxes                             |                                      | - |                                                                     |   | -        |  |   | -          
|Net income (loss)                        | $                                    | - |                                                                     | $ | (54,259) |  | $ | (2,207,579)

NOTE 4  RELATED PARTY TRANSACTIONS  Related Party Loans  During the three months ended March
31, 2009, shareholders or entities controlled by them loaned $4,455 to the
Company.  At March 31, 2009, the Company owed a total of $55,024 to related
parties, all of which accrues interest at 8% per annum and is due on demand.
 During the three months ended March 31, 2009 and 2008, the Company accrued
interest expense on related party loans totaling $1,056 and $7,481,
respectively.


9


LIPIDVIRO TECH,
INC. (A Development Stage Company) NOTES TO THE UNAUDITED CONDENSED FINANCIAL
STATEMENTS  NOTE 5  INCOME TAXES  At March 31, 2009, the Company has available unused
federal net operating loss carryovers of approximately $122,000 which may be
applied against future taxable income and which expire in 2028 and 2029.
 The Company has decided that there is only a remote likelihood of any
future operations of the Company generating taxable income in the State of Utah.
Therefore, the Company has eliminated the deferred tax asset of approximately
$4,500 corresponding to the approximately $106,000 unused Utah net operating
loss carryover from the prior year.  The amount of and ultimate realization of the benefits
from the net operating loss carryovers for income tax purposes is dependent, in
part, upon the tax laws in effect, the future earnings of the Company and other
future events, the effects of which cannot be determined.  Additionally, if
there are substantial changes in the Companys ownership, there may be an annual
limitation on the amount of net operating loss carryovers that can be utilized.
 Because of the uncertainty surrounding the realization of the net
operating loss carryovers, the Company has established a valuation allowance
equal to the tax effect of the loss carryovers and, therefore, no deferred tax
asset has been recognized in the financial statements. The net deferred tax
assets are approximately $18,300 and $20,400 as of March 31, 2009 and December
31, 2008, respectively, with an offsetting valuation allowance of the same
amount, resulting in a change in the valuation allowance of approximately $2,100
during the three months ended March 31, 2009.  NOTE 6  SUBSEQUENT EVENTS  In April 2009, shareholders or entities controlled by
them loaned an additional $2,835 to the Company.


10


Item 2. Managements Discussion and Analysis of Financial Condition and
Results of Operations.  Forward-looking Statements  Statements made in this Quarterly Report which are not
purely historical are forward-looking statements with respect to the goals, plan
objectives, intentions, expectations, financial condition, results of
operations, future performance and our business, including, without limitation,
(i) our ability to raise capital, and (ii) statements preceded by, followed by
or that include the words may, would, could, should, expects,
projects, anticipates, believes, estimates, plans, intends,
targets or similar expressions.  Forward-looking statements involve inherent risks and
uncertainties, and important factors (many of which are beyond our control) that
could cause actual results to differ materially from those set forth in the
forward-looking statements, including the following, general economic or
industry conditions, nationally and/or in the communities in which we may
conduct business, changes in the interest rate environment, legislation or
regulatory requirements, conditions of the securities markets, our ability to
raise capital, changes in accounting principles, policies or guidelines,
financial or political instability, acts of war or terrorism, other economic,
competitive, governmental, regulatory and technical factors affecting our
current or potential business and related matters.  Accordingly, results actually achieved may differ
materially from expected results in these statements.  Forward-looking
statements speak only as of the date they are made.  We do not undertake,
and specifically disclaim, any obligation to update any forward-looking
statements to reflect events or circumstances occurring after the date of such
statements.  Plan of Operation  On September 29, 2008, LipidViro Tech,
Inc., a Utah corporation (LipidViro Utah), which was a wholly-owned subsidiary
of the Company, completed the transfer to AcquiSci, Inc., a New Jersey
corporation, of certain technology that comprised substantially all of its
assets and, by extension, substantially all of the Companys assets (the
Technology).  On September 30, 2008, following the
completion of the Technology disposition, the Company executed a Bill of Sale by
which it assigned to Benedente Holdings, LLC, a Wyoming limited liability
company, 9,843,750 shares of common stock of LipidViro Utah (the Shares),
which Shares constituted all of the issued and outstanding shares of LipidViro
Utah common stock.  Benedente is controlled by Steven Keyser, who is a
director of the Company.  For more information regarding the disposition of
Technology and the disposition of LipidViro Utah, see our 8-K Current Report
dated September 29, 2008.  Our plan of operation for the next 12 months is to: (i)
consider guidelines of industries in which we may have an interest; (ii) adopt a
business plan regarding engaging in the business of any selected industry; and
(iii) to commence such operations through funding and/or the acquisition of a
going concern engaged in any industry selected.  During the next 12 months, our only foreseeable cash
requirements will relate to the payment of our Securities and Exchange
Commission and Exchange Act reporting filing expenses, including associated
legal and accounting fees; costs incident to reviewing or investigating any
potential business venture; and maintaining our good standing as a corporation
in our state of organization.  We anticipate that these funds will be
provided to us in the form of loans from Jenson Services.  There are no
written agreements requiring Jenson Services to provide these cash resources;
and to the extent funds are provided, such funds will bear no interest (though
an interest expense of 10% has been imputed on funds advanced) and will be due
on demand.  As of the date of this Quarterly Report, we have not actively
begun to seek any business or acquisition candidate.  Results of Operations  During the quarters ended March 31, 2009, and 2008, we
had losses from continuing operations of $15,994 and $56,327 and income and
(loss) from discontinued operations of $0 and ($54,259) for a net income and
(loss) of ($15,994) and ($110,586), respectively.  Liquidity  We have no current cash resources.


11


During the next
12 months, our only foreseeable cash requirements will relate to the payment of
our Securities and Exchange Commission and Exchange Act reporting filing
expenses, including associated legal and accounting fees; costs incident to
reviewing or investigating any potential business venture; and maintaining our
good standing as a corporation in the State of Nevada.  We do not have any
cash reserves to pay for our administrative expenses for the next 12 months.
 In the event that additional funding is required in order to keep us in
good standing, we may attempt to raise such funding through loans or through
additional sales of our common stock.    Item 3.  Quantitative and
Qualitative Disclosures About Market Risk.  Not required.  Item 4T.  Controls and Procedures.  Evaluation of disclosure controls and procedures  Our management, with the participation of our chief
executive officer and chief financial officer, evaluated the effectiveness of
our disclosure controls and procedures as defined in Rule 13a-15(e) under the
Exchange Act as of the end of the period covered by this Quarterly Report on
Form 10-Q.  In designing and evaluating the disclosure controls and
procedures, our management recognized that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives.  In addition, the design of
disclosure controls and procedures must reflect the fact that there are resource
constraints and that management is required to apply its judgment in evaluating
the benefits of possible controls and procedures relative to their costs.
 The design of any disclosure controls and procedures also is based in part
upon certain assumptions about the likelihood of future events and there can be
no assurance that any design will succeed in achieving its stated goals under
all potential future conditions.  Based on that evaluation, our chief executive officer and
chief financial officer concluded that, as of March 31, 2009, our disclosure
controls and procedures were, subject to the limitations noted above, effective
to provide reasonable assurance that information we are required to disclose in
reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in Securities and
Exchange Commission rules, regulations and forms, and that such information is
accumulated and communicated to our management, including our chief executive
officer and chief financial officer, as appropriate, to allow timely decisions
regarding required disclosure.


12


Changes in internal control
over financial reporting  Our management, with the participation of
the chief executive officer and chief financial officer, has concluded there
were no significant changes in our internal controls over financial reporting
that occurred during our last fiscal quarter that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting.  PART II - OTHER INFORMATION   Item 1. Legal Proceedings.  None; not applicable.  Item 1A.  Risk
Factors.  Not required.   Item 2. Unregistered Sales of Equity Securities and
Use of Proceeds.  None; not applicable.   Item 3. Defaults Upon Senior Securities.  None; not applicable.   Item 4. Submission of Matters to a Vote of Security
Holders.  None; not applicable.   Item 5. Other Information.  In April 2009, shareholders or entities controlled by
them loaned an additional $2,835 to the Company.  Effective as of May 6, 2009, which is
subsequent to the end of the period covered by this Report, Kenneth P. Hamik
tendered his resignation as President, CEO and a director of the Company.
 Mr. Hamiks resignation was not due to any disagreement with the Company
on any matter relating to the Companys operations, policies or practices, or
disagreements with the Company.  Steven Keyser, the Companys sole
remaining director: (i) appointed Thomas J. Howells to fill a vacancy on the
Board of Directors, effective as of May 6, 2009, to serve until the next annual
meeting of the Companys stockholders or his prior resignation or termination;
(ii) accepted Mr. Hamiks resignation; (iii) appointed Mr. Howells to serve as
the Companys CEO and President until the next annual meeting of the Companys
Board of Directors or his prior resignation or termination; (iv) authorized the
change of the Companys business address to 4685 S. Highland Drive, Suite 202,
Salt Lake City, Utah 84117, which is Mr. Howells business address; and (v)
authorized Mr. Howells to update the Companys record address with the Nevada
Secretary of State, the Companys registered agent in Nevada, and all other
entities with which the Company conducts business.  For more information
see our 8-K Current Report dated May 6, 2009, and filed with the Securities and
Exchange Commission on May 8, 2009.  Item 6. Exhibits.   Exhibit No.                       Identification
of Exhibit  31

32
Certification of Thomas J. Howells Pursuant to
Section 302 of the Sarbanes-Oxley Act.

Certification of Thomas J. Howells Pursuant to 18
U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act.    SIGNATURES


13


Pursuant to
the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized  LIPIDVIRO TECH, INC.  Date:
May 12, 2009

By:
/s/Thomas J. HowellsThomas J. Howells, President, Chief Executive
Officer and DirectorDate:
May 12, 2009

By:
/s/Steven KeyserSteven Keyser, Director


14